Mongolia Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Mongolia Healthcare Journal.

Press releases published on November 9, 2026

Nov. 9, 2026

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Indeterminate GlobeNewswire

Nov. 9, 2026

Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer  

Indeterminate GlobeNewswire

Nov. 9, 2026

Epitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancé  

Indeterminate GlobeNewswire

Nov. 9, 2026

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026

Indeterminate GlobeNewswire

Nov. 9, 2026

iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells

Indeterminate GlobeNewswire

Nov. 9, 2026

Truveta launches care insights solution to inform pre-launch planning, then follow treatments after approval and into clinical practice

Indeterminate GlobeNewswire

Nov. 9, 2026

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

Indeterminate GlobeNewswire

Nov. 9, 2026

GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027

Indeterminate GlobeNewswire

Nov. 9, 2026

GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027

Indeterminate GlobeNewswire

Nov. 9, 2026

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

Indeterminate GlobeNewswire

Nov. 9, 2026

Valneva annonce des résultats positifs de phase 2 pour son candidat vaccin tétravalent contre la shigellose S4V2

Indeterminate GlobeNewswire

Nov. 9, 2026

Essential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiency

Indeterminate GlobeNewswire

Nov. 9, 2026

argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Indeterminate GlobeNewswire

Nov. 9, 2026

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Indeterminate GlobeNewswire

Nov. 9, 2026

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Indeterminate GlobeNewswire

Nov. 9, 2026

Fangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care Innovation

Indeterminate GlobeNewswire

Nov. 9, 2026

InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China

Indeterminate GlobeNewswire